BioWorld

Jan. 23, 2007

PharmAthene Gaining Listing, Cash Through Reverse Merger

PharmAthene Inc. is gaining a public listing and up to $70 million in cash through a planned merger with Healthcare Acquisition Corp., a deal coming months after another proposed merged by PharmAthene fell through. (BioWorld Today) Read More

Analyst: Roche's EPO Drug Near Match With Aranesp

Two Toxins Make For Vicious Cycle In Common Staph Strain

Chinese Firm 3SBIO Seeking Nasdaq Listing, $124M In IPO

Bionovo Raises $15.7M Privately For Cancer, Women's Health

Other News To Note

Clinic Roundup

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Jan 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...